Neurogene to Participate in Upcoming Conferences

Rhea-AI Summary

Neurogene (NASDAQ: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, announced participation in several upcoming conferences.

At the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, management will present a corporate overview and meet with investors.

On June 18-19, 2024, at the IRSF Rett Syndrome Scientific Meeting, interim safety data from the NGN-401 gene therapy trial for Rett syndrome will be presented by management and Dr. Bernhard Suter.

Additionally, Neurogene will participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit on June 21, 2024. Live webcasts of these events will be available on Neurogene’s Investor Relations webpage.

Positive

• Neurogene's participation in the Goldman Sachs 45th Annual Global Healthcare Conference and the TD Cowen Genetic Medicines & RNA Summit demonstrates strong industry engagement.
• The presentation of interim safety data from the NGN-401 trial for Rett syndrome suggests progress in clinical research.
• Live webcasts of the events will enhance transparency and accessibility for investors.

Negative

• The press release lacks detailed financial data, providing no updates on revenue or earnings.
• No new clinical milestones or approvals were reported, potentially indicating slower-than-expected progress.
• The focus on conference participation may not directly address investor concerns about profitability or long-term growth.

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:

Goldman Sachs 45th Annual Global Healthcare Conference
Format: Management will present a corporate overview and participate in investor meetings
Date: Wednesday, June 12 at 1:20 p.m. ET

2024 IRSF (International Rett Syndrome Foundation) Rett Syndrome Scientific Meeting
Format: Management and Bernhard Suter, M.D., Medical Director of the Blue Bird Circle Rett Center at Texas Children’s Hospital, Associate Professor of Pediatrics and Neurology at Baylor College of Medicine, and principal investigator in the Phase 1/2 NGN-401 gene therapy trial for Rett syndrome, will present interim safety data from the NGN-401 trial
Date: Tuesday, June 18 at 5:15 p.m. MT (poster presentation), and Wednesday, June 19 at 11:30 a.m. MT (oral presentation)

TD Cowen Genetic Medicines & RNA Summit
Format: Management will participate in a fireside chat
Date: Friday, June 21 at 10:40 a.m. ET

Live webcasts of the corporate overview and fireside chat will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the events will also be available for a limited time.

About Neurogene
The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and is expected to support pivotal clinical development activities. For more information, visit www.neurogene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605485474/en/

Company:

Cara Mayfield

Vice President, Corporate Affairs

cara.mayfield@neurogene.com

Investor:

Melissa Forst

Argot Partners

Neurogene@argotpartners.com

Source: Neurogene Inc.

FAQ

What events will Neurogene participate in according to the latest press release?

Neurogene will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, the IRSF Rett Syndrome Scientific Meeting, and the TD Cowen Genetic Medicines & RNA Summit.

When is Neurogene presenting at the Goldman Sachs 45th Annual Global Healthcare Conference?

Neurogene will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 1:20 p.m. ET.

What will be presented at the IRSF Rett Syndrome Scientific Meeting?

Interim safety data from the NGN-401 gene therapy trial for Rett syndrome will be presented at the IRSF Rett Syndrome Scientific Meeting.

Who will present the NGN-401 data for Neurogene?

Dr. Bernhard Suter, Medical Director at Texas Children’s Hospital and principal investigator of the NGN-401 trial, will present the interim safety data.

How can investors access Neurogene's conference presentations?

Live webcasts of Neurogene's conference presentations will be available on the Investor Relations section of the company’s website.